Clinical Trial Update: A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors [Phase 1]

View source ↗

Summary

A completed Phase 1 study evaluating the safety and pharmacokinetics of KTN3379 in adults with advanced tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• KTN3379 (KTN3379)

Snippet

Sponsor: Celldex Therapeutics | Conditions: Advanced Cancer | Phase 1 | Status: COMPLETED